MARLBOROUGH, Mass.,
Oct. 16, 2018 /PRNewswire/ -- Boston Scientific
Corporation (NYSE: BSX) today announced the close of its
acquisition of Augmenix, Inc., a privately-held company that
developed and commercialized the SpaceOAR® Hydrogel
System to help reduce common and debilitating side effects that men
may experience after receiving radiotherapy to treat prostate
cancer. The biodegradable SpaceOAR hydrogel is injected between the
rectum and prostate to decrease a patient's exposure to rectal
radiation and thereby reduce rectal radiation injury – one of the
most common complications of prostate radiotherapy.
"This close marks the third completed acquisition in 2018 for
the company's Urology and Pelvic Health portfolio, further building
upon our substantial momentum in this category," said Dave Pierce, executive vice president and
president, MedSurg, Boston Scientific. "The addition of the
SpaceOAR Hydrogel System, which has been used in over 30,000
patients worldwide and reviewed by more than 55 peer-reviewed
publications, continues to strengthen our leadership in prostate
health."
The addition of the SpaceOAR Hydrogel System reinforces the
company's commitment to prostate health with a solution that
addresses the need to protect healthy organs at risk (OAR) during
prostate cancer radiotherapy. The SpaceOAR Hydrogel System will
also expand the company's prostate health portfolio, which includes
therapies to treat benign prostatic hyperplasia, including the
Rezūm® System, the GreenLight XPS™ Laser
Therapy System and holmium laser platforms.
Boston Scientific announced a definitive agreement to acquire
Augmenix on September 6, 2018 for
$500 million in up-front cash and up
to $100 million for reaching
sales-based milestones.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect,"
"project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs,
assumptions and estimates using information available to us at the
time and are not intended to be guarantees of future events or
performance. These forward-looking statements include, among other
things, statements regarding our business plans, regulatory
approvals, product development and product performance and impact.
If our underlying assumptions turn out to be incorrect, or if
certain risks or uncertainties materialize, actual results could
vary materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some
cases, have affected and in the future (together with other
factors) could affect our ability to implement our business
strategy and may cause actual results to differ materially from
those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All of
these factors are difficult or impossible to predict accurately and
many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties
that may affect our future operations, see Part I, Item 1A –
Risk Factors in our most recent Annual Report on Form 10-K
filed with the Securities and Exchange Commission, which we may
update in Part II, Item 1A – Risk Factors in Quarterly
Reports on Form 10-Q we have filed or will file hereafter. We
disclaim any intention or obligation to publicly update or revise
any forward-looking statements to reflect any change in our
expectations or in events, conditions or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements. This cautionary statement is applicable
to all forward-looking statements contained in this document.
Use of Non-GAAP Financial Measures
To supplement our consolidated financial statements presented on
a GAAP basis, we disclose certain non-GAAP financial measures,
including adjusted net income and adjusted net income (earnings)
per share that excludes certain charges and/or credits, such as
amortization expense and acquisition-related net charges (credits).
These non-GAAP financial measures are not in accordance with
generally accepted accounting principles in the United
States and should not be considered in isolation from or as a
replacement for the most directly comparable GAAP financial
measures. Further, other companies may calculate these non-GAAP
financial measures differently than we do, which may limit the
usefulness of those measures for comparative purposes. For further
information regarding our non-GAAP measures, see Part II, Item 7 -
Management's Discussion and Analysis of Financial Condition and
Results of Operations in our most recent Annual Report on Form
10-K, which we may update in Quarterly Reports on Form 10-Q we have
filed or will file hereafter.
CONTACTS
Abhi Basu
Media Relations
508-683-4797 (office)
Abhi.Basu@bsci.com
Susie Lisa, CFA
Investor Relations
508-683-5565 (office)
BSXInvestorRelations@bsci.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/boston-scientific-closes-acquisition-of-augmenix-inc-300732057.html
SOURCE Boston Scientific Corporation